These studies evaluated the 24-h forced expiratory volume in 1 sec (FEV1) profile of once-daily (QD)
olodaterol compared to placebo and twice-daily (BID)
formoterol in patients with moderate to very severe
chronic obstructive pulmonary disease. In two replicate, randomized, double-blind, double-dummy, four-way crossover studies, patients received
olodaterol 5 and 10 μg QD,
formoterol 12 μg BID, or placebo for 6 weeks in addition to usual-care background maintenance
therapy. Co-primary end points were FEV1 area under the curve from 0-12 h (AUC0-12) response (change from baseline) and FEV1 AUC from 12-24 h (AUC12-24) response after 6 weeks, with FEV1 AUC from 0-24 h response identified as a key secondary end point. Other secondary end points included FEV1 AUC from 0-3 h and trough FEV1 responses, as well as corresponding forced vital capacity responses. With both
olodaterol doses, FEV1 increased to near-maximal 30 min post-morning dose, which was sustained over 24 h. FEV1 also increased within 30 min post-morning dose of
formoterol and was sustained over 12 h; the second
formoterol dose resulted in a further increase, sustained for an additional 12 h. FEV1 AUC0-12 and AUC12-24 responses with both QD
olodaterol doses and BID
formoterol were significantly greater than placebo at 6 weeks (P < .0001). Secondary end-point outcomes were consistent with those of the co-primary end points. These data, together with those from the wider phase III clinical program, provide evidence for the 24-h
bronchodilator efficacy of
olodaterol QD in this patient population.
TRIAL REGISTRY: ClinicalTrials.gov; NCT00931385 and NCT00932646.